UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000035753 |
|---|---|
| Receipt number | R000040728 |
| Scientific Title | The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial |
| Date of disclosure of the study information | 2019/02/02 |
| Last modified on | 2022/05/26 20:58:42 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2019/02/02 16:01:11 | ||
| 2 | Update | 2019/03/28 16:48:34 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel Study ID_2 Org. issuing International ID_2 Org. issuing International ID_2 |
|
| 3 | Update | 2019/03/28 16:51:19 | Recruitment status Date of IRB Anticipated trial start date Last follow-up date |
|
| 4 | Update | 2019/07/05 22:21:59 | Organization Institutions |
|
| 5 | Update | 2019/11/30 13:01:51 | Key exclusion criteria Key exclusion criteria |
|
| 6 | Update | 2020/06/01 17:13:17 | Recruitment status |
|
| 7 | Update | 2021/08/05 09:17:19 | URL releasing protocol Number of participants that the trial has enrolled |
|
| 8 | Update | 2021/08/05 09:19:47 | Last follow-up date |
|
| 9 | Update | 2022/02/04 13:19:11 | Last follow-up date Date trial data considered complete Date analysis concluded |
|
| 10 | Update | 2022/02/04 13:21:01 | Recruitment status |
|
| 11 | Update | 2022/05/26 20:58:42 | Date analysis concluded |
